酒石酸美托洛尔联合贝那普利治疗扩张型心肌病慢性心功能不全的疗效

JOURNAL OF HEZE MEDICAL COLLEGE 第31卷第3期VOL.31NO.3

菏泽医学专科学校学报2019年2019

扩张型心肌病为临床常见心肌病，目前其发病机制尚未完全清楚，临床最常见特征是双心室收缩、舒张功能受损，诱发血栓栓塞、心力衰竭等，危害严重[1]。近几年临床治疗扩张型心肌病慢性心功能不全仍然以扩血管、强心、利尿等措施为主，但部分患者疗效欠佳。相关研究指出，左室结构重塑与肾素-血管紧张素-醛固酮系统(RAAS )生物活性密切相关，改善肾素-血管紧张素系统(RAS )生物活性，对抑制心室重构，改善扩张型心肌病慢性心功能不全患者心功能具有积极作用[2,3]。本研究旨在从心功能、安全性等方面探讨酒石酸美托洛尔联合贝那普利治疗扩张型心肌病慢性心功能不全的临床效果，现报道DOI:10.3969/j.issn.1008-4118.2019.03.013

酒石酸美托洛尔联合贝那普利治疗扩张型

心肌病慢性心功能不全的疗效

孙前进

（济源市第二人民医院，河南济源459000）

摘要：目的观察酒石酸美托洛尔、贝那普利联合治疗扩张型心肌病慢性心功能不全的临床效

果。方法选取扩张型心肌病慢性心功能不全患者77例，随机分为联合组和对照组，联合组39例、对照组38例。对照组予以酒石酸美托洛尔治疗，联合组予以酒石酸美托洛尔、贝那普利联合治疗。对比两组疗效、不良反应、治疗前后左室射血分数（LVEF ）、左室舒张末期内径（LVEDD ）、左室收缩末期内径（LVSDD ）。结果两组疗效比较，P ＜0.05；治疗6周后两组LVEF 、LVEDD 、LVSDD 比较，P 均＜0.05；两组不良反应比较，P ＞0.05。结论酒石酸美托洛尔联合贝那普利能有效改善心功能，提高临床疗效，且不良反应发生率低，安全性高。

关键词：酒石酸美托洛尔；贝那普利；扩张型心肌病；慢性心功能不全

中图分类号:R541文献标识码:A 文章编号:1008-4118（2019）03-0038-03

The efficacy of metoprolol tartrate combined with benazepril in the treatment of

dilated cardiomyopathy with chronic cardiac insufficiency

SUN Qianjin

(Jiyuan Second People's Hospital,Jiyuan 459000,Henan)

Abstract:Objective To study the clinical effect of metoprolol tartrate and benazepril in the treatment of dilated

cardiomyopathy with chronic cardiac insufficiency.Methods 77patients with dilated cardiomyopathy with chronic cardi?ac insufficiency were enrolled and randomly divided into two groups,39cases in the combination group and 38cases in the control group.The control group was treated with metoprolol tartrate and the combination group was treated with metopro?lol tartrate combined with benazepril.The efficacy,adverse reactions,left ventricular ejection fraction (LVEF),left ventricu?lar end-diastolic diameter (LVEDD)and left ventricular end-systolic diameter (LVSDD)before treatment and 6weeks af?ter treatment were compared between the two groups.Results The total effective rate of the combination group was high?er than that of the control group (P <0.05).After 6weeks of treatment,the LVEF of the combination group was higher than that of the control group,and the LVEDD and LVSDD were lower than the control group (P <0.05).There was no signifi?cant difference in the incidence of adverse reactions (P >0.05).Conclusion Metoprolol tartrate and benazepril can effec?tively improve cardiac function,improve clinical efficacy,which has low adverse reactions and high safety.

Key words:Metoprolol tartrate;Benazepril;Dilated cardiomyopathy;Chronic cardiac insufficiency

38